PL4003293T3 - Rozwój farmaceutyczny - Google Patents
Rozwój farmaceutycznyInfo
- Publication number
- PL4003293T3 PL4003293T3 PL20751254.2T PL20751254T PL4003293T3 PL 4003293 T3 PL4003293 T3 PL 4003293T3 PL 20751254 T PL20751254 T PL 20751254T PL 4003293 T3 PL4003293 T3 PL 4003293T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical development
- pharmaceutical
- development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910787.9A GB201910787D0 (en) | 2019-07-29 | 2019-07-29 | Pharmaceutical development |
| PCT/GB2020/051810 WO2021019234A1 (en) | 2019-07-29 | 2020-07-28 | Pharmaceutical development |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4003293T3 true PL4003293T3 (pl) | 2025-09-01 |
Family
ID=67990469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20751254.2T PL4003293T3 (pl) | 2019-07-29 | 2020-07-28 | Rozwój farmaceutyczny |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220257699A1 (pl) |
| EP (2) | EP4003293B1 (pl) |
| JP (1) | JP7743076B2 (pl) |
| CN (1) | CN114514033A (pl) |
| CA (1) | CA3144541A1 (pl) |
| GB (1) | GB201910787D0 (pl) |
| PL (1) | PL4003293T3 (pl) |
| SA (1) | SA522431528B1 (pl) |
| WO (1) | WO2021019234A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112546030A (zh) * | 2019-09-26 | 2021-03-26 | 盈科瑞(天津)创新医药研究有限公司 | 一种吸入用多粘菌素e甲磺酸钠溶液及其制备方法 |
| EP3995370B1 (en) * | 2020-11-04 | 2025-04-30 | Volvo Truck Corporation | A vehicle motion management system and a motion support system for a vehicle |
| CN113121646B (zh) * | 2021-03-02 | 2022-09-13 | 河北圣雪大成制药有限责任公司 | 一种结晶工艺制备多粘菌素甲磺酸钠的方法 |
| CN116203173A (zh) * | 2022-12-31 | 2023-06-02 | 中国人民解放军空军军医大学 | 一种基于lc-ms/ms法同时测定人血清中多粘菌素e1和多粘菌素e2浓度的方法 |
| CN119523952A (zh) * | 2024-10-17 | 2025-02-28 | 河北医科大学 | 一种多黏菌素吸入液体制剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879145B (zh) * | 2009-09-16 | 2011-04-20 | 朗天药业(湖北)有限公司 | 抗hiv药物注射用齐多夫定及其制备工艺 |
| CN104043103B (zh) * | 2013-03-12 | 2015-08-05 | 江苏奥赛康药业股份有限公司 | 一种多黏菌素e甲磺酸钠冻干制剂及其制备方法 |
| GB201305277D0 (en) * | 2013-03-22 | 2013-05-01 | Helperby Therapeutics Ltd | Novel combination and use |
| TW201522364A (zh) | 2013-06-07 | 2015-06-16 | Xellia Pharmaceuticals Aps | 黏菌素甲磺酸鈉(cms)之定性方法 |
| GB201401617D0 (en) * | 2014-01-30 | 2014-03-19 | Helperby Therapeutics Ltd | Novel combination and use |
| GB201521771D0 (en) | 2015-12-10 | 2016-01-27 | Helperby Therapeutics Ltd | Formulation |
| GB201704620D0 (en) * | 2017-03-23 | 2017-05-10 | Helperby Therapeautics Ltd | Combinations |
-
2019
- 2019-07-29 GB GBGB1910787.9A patent/GB201910787D0/en not_active Ceased
-
2020
- 2020-07-28 JP JP2022506140A patent/JP7743076B2/ja active Active
- 2020-07-28 WO PCT/GB2020/051810 patent/WO2021019234A1/en not_active Ceased
- 2020-07-28 US US17/630,645 patent/US20220257699A1/en active Pending
- 2020-07-28 EP EP20751254.2A patent/EP4003293B1/en active Active
- 2020-07-28 EP EP25180290.6A patent/EP4591874A3/en active Pending
- 2020-07-28 CN CN202080068232.4A patent/CN114514033A/zh active Pending
- 2020-07-28 CA CA3144541A patent/CA3144541A1/en active Pending
- 2020-07-28 PL PL20751254.2T patent/PL4003293T3/pl unknown
-
2022
- 2022-01-27 SA SA522431528A patent/SA522431528B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7743076B2 (ja) | 2025-09-24 |
| SA522431528B1 (ar) | 2024-07-15 |
| US20220257699A1 (en) | 2022-08-18 |
| CN114514033A (zh) | 2022-05-17 |
| EP4003293A1 (en) | 2022-06-01 |
| CA3144541A1 (en) | 2021-02-04 |
| WO2021019234A1 (en) | 2021-02-04 |
| EP4003293B1 (en) | 2025-06-04 |
| EP4591874A2 (en) | 2025-07-30 |
| EP4591874A3 (en) | 2025-09-10 |
| JP2022542395A (ja) | 2022-10-03 |
| EP4003293C0 (en) | 2025-06-04 |
| GB201910787D0 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276232A (en) | pharmaceutical compounds | |
| GB201911928D0 (en) | Pharmaceutical compounds | |
| GB2572126B (en) | Pharmaceutical | |
| GB2569961B (en) | Pharmaceutical | |
| GB2572125B (en) | Pharmaceutical | |
| GB201810245D0 (en) | Pharmaceutical compounds | |
| EP3638658C0 (en) | PHARMACEUTICAL COMPOUNDS | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| GB201810239D0 (en) | Pharmaceutical compounds | |
| GB201819961D0 (en) | Pharmaceutical compounds | |
| PL4003293T3 (pl) | Rozwój farmaceutyczny | |
| GB201819960D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB201801562D0 (en) | Pharmaceutical compounds | |
| GB201901989D0 (en) | Pharmaceutical combinations | |
| IL277334A (en) | Pharmaceutical combinations | |
| IL291570A (en) | Pharmaceutical preparations | |
| GB201800378D0 (en) | Pharmaceutical compounds | |
| IL279334A (en) | Pharmaceutical combinations | |
| GB201816369D0 (en) | Pharmaceutical compounds | |
| IL283273A (en) | Pharmacy practices | |
| PL3996688T3 (pl) | Preparat farmaceutyczny | |
| ZA202006346B (en) | Pharmaceutical preparation |